In this context, MYCN represents an ideal therapeutic target given its correlation with rapid tumor progression, poor prognosis and the limited expression in normal cells and tissue, suggesting high tolerability for a MYCN-targeted approach [3, 6]. This evidence concerns the gene MYCN and neoplasm.